EMILY BOLLINGER: Open Payments
NPI 1215708235 · KANSAS CITY, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,001 in 67 payments from 27 companies in 2025. Trend: 2023 $0 · 2024 $1,143 · 2025 $2,001
Food & beverage: $2,001
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 5 | $543 |
| Novo Nordisk Inc | 7 | $213 |
| Dexcom, Inc. | 3 | $177 |
| ABBVIE INC. | 10 | $169 |
| Merck Sharp & Dohme LLC | 2 | $130 |
| Amgen Inc. | 5 | $93 |
| Abbott Laboratories | 4 | $73 |
| Sumitomo Pharma America, Inc. | 3 | $59 |
| PFIZER INC. | 3 | $54 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $50 |
Products named: AIRSUPRA, Dexcom G6 Transmitter, Wegovy, CAPVAXIVE, VRAYLAR, FREESTYLE LIBRE 3, GEMTESA, OTEZLA.
Industry payments across MO — which companies pay providers there.
